Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

611.O4.8 Acute Leukemias – Innovative Approaches to Diagnosis, Prognostication, and Identification of Therapeutic Targets

Tuesday, December 9, 2008: 7:00 AM-9:00 AM
Yerba Buena Ballroom Salon 9 (San Francisco Marriott)
Moderators:
H. Ruud Delwel and Louis M. Staudt, MD., Ph.D.
7:00 AM
The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group

Torsten Haferlach, MD1, Alexander Kohlmann, PhD1, Giuseppe Basso, MD1*, Marie-Christine Béné, PhD1*, Sabina Chiaretti, MD1*, James R. Downing, MD2, Jesús-María Hernández, MD1*, Wolf-Karsten Hofmann, MD1*, Thomas J. Kipps, MD, PhD3, Evelyn S Koay, MD4*, Geertruy Te Kronnie, PhD1, Wei-min Liu, PhD5*, Elizabeth MacIntyre, PhD1*, Ken I Mills, PhD1, Peter Papenhausen, PhD6, Claude Preudhomme, PhD1, Laura Z Rassenti, PhD7, Sheila A Shurtleff, PhD2*, John De Vos, PhD1*, Allen E Yeoh, MD4*, P. Mickey Williams, PhD5, Lothar Wieczorek, PhD5* and Robert Foŕ, MD1

1MILE Study Group, on Behalf of European LeukemiaNet (ELN, WP13), Munich, Germany
2Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN
3Moores UCSD Cancer Center, CLL Research Consortium, La Jolla, CA
4Department of Paediatrics, National University of Singapore, Singapore
5Roche Molecular Systems, Inc., Pleasanton, CA
6Laboratory Corporation of America, Research Triangle Park, NC
7UCSD, Moores Cancer Center, La Jolla, CA

7:15 AM
Early Diagnosis and Molecular-Based Treatment of Very Highly Resistant Acute Lymphoblastic Leukemia in Childhood

Gunnar Cario, MD1*, Andre Schrauder, MD1*, Anja Moericke, MD1*, Jean-Pierre Bourquin, MD2*, Martin Schrappe, MD1 and Martin Stanulla, MD3*

1Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
2University Childrens Hospital, Oncology, University of Zurich, Zurich, Switzerland
3Dept. of Ped. Hematology, Medical School Hannover, Germany

7:30 AM
Time to Leukemia (TTL) in NOD/SCID Mice Determines Patient Outcome and Is Characterized by a 5 Genes Signature Associated with Relapse

Lueder Hinrich Meyer, MD1*, Andrea Zangrando, PhD2*, Sarah M. Eckhoff, MD1*, Manon Queudeville, MD1*, Elena Vendramini2*, Giuseppe Basso, MD2*, Geertruy te Kronnie, PhD2* and Klaus-Michael Debatin, MD1

1Department of Pediatrics and Adolescent Medicine, University of Ulm, Ulm, Germany
2Department of Pediatrics, Laboratory of Pediatric Oncohematology, University of Padova, Padova, Italy

7:45 AM
Epigenetic Signatures Identify New Clinically Relevant Subtypes and Define Gene Regulatory Patterns in Patients with Acute Myeloid Leukemia (AML)

Maria E Figueroa, MD1, Sanne Lugthart, MD2*, Yushan Li1*, Claudia Erpelinck-Verschueren2*, Paul J Christos, MS, MPH3*, Madhu Mazumdar, PhD3*, Bob Löwenberg, MD, PhD2*, John Greally, MB, PhD4*, Peter JM Valk, PhD2*, Ruud Delwel, PhD2* and Ari Melnick, MD1*

1Medicine - Division of Hematology Oncology, Weill Cornell Medical College, New York, NY
2Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
3Biostatistics and Epidemiology, Weill Cornell Medical College, New York, NY
4Department of Medicine and Molecular Genetics, Albert Einstein College of Medicine, Bronx, NY

8:00 AM
Two Different EVI1 Expressing Poor-Risk AML Subgroups with Distinct Epigenetic Signatures Uncovered by Genome Wide DNA Methylation Profiling

Sanne Lugthart, MD1*, Maria E Figueroa, MD2, Peter JM Valk, PhD1*, Yushan Li2*, Claudia Erpelinck-Verschueren1*, John Greally, MB, PhD3*, Bob Löwenberg, MD, PhD1*, Ari Melnick, MD2* and Ruud Delwel, PhD1

1Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
2Medicine - Division of Hematology Oncology, Weill Cornell Medical College, New York, NY
3Department of Medicine and Molecular Genetics, Albert Einstein College of Medicine, Bronx, NY

8:15 AM
RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients

Jeffrey W Tyner, PhD1*, Marc Loriaux, MD, PhD1*, Stephanie G Willis1*, Bill Chang, MD, PhD1, Vincent T Bicocca1*, Stephen Oh, MD, PhD2*, Iris H.I.M. Hollink, MD3*, Stefanie Segers3*, Monique L. den Boer3*, C. M Zwaan, MD, PhD3, Jason R. Gotlib2*, Michael W.N. Deininger, MD1 and Brian J. Druker1

1Oregon Health & Science University Cancer Institute, Portland, OR
2Stanford Cancer Center, Stanford Univ., Stanford, CA
3Erasmus MC/Sophia Children's Hospital, Rotterdam, Netherlands

8:30 AM
Proteomic Profiling of 150 Proteins in 511 Acute Myelogenous Leukemia (AML) Patient Samples Using Reverse Phase Proteins Arrays (RPPA) Reveals Recurrent Proteins Expression Signatures with Prognostic Implications

Steven M. Kornblau, MD, YiHua Qiu*, Wenjing Chen*, Phillip Chou*, Lance Blau*, Ha Nashino*, Farhad Ravandi*, Michael Andreeff*, Hagop Kantarjian*, Shannon Neeley*, Zhenlin Ju*, Nianxiang Zhang* and Kevin R. Coombes*

M.D. Anderson Cancer Center, Houston, TX

8:45 AM
Detection of Leukemia in MLL-AF9 Transgenic Mice Using Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy

Deborah DeRyckere, Ph.D.1*, Natalie Serkova, Ph.D.2*, Margaret E. Macy, M.D.1, Lori A. Gardner, B.A.1*, Paul Jedlicka, M.D., Ph.D.3*, Kendra M. Hasebroock, B.S.2* and Lia Gore, M.D.1

1Pediatrics, Section of Hematology, Oncology, and Bone Marrow Transplantation, University of Colorado Denver, Aurora, CO
2Anesthesiology, University of Colorado Denver, Aurora, CO
3Pathology, University of Colorado Denver, Aurora, CO

*signifies non-member of ASH